China Isotope & Radiation's (HKG:1763) Problems Go Beyond Weak Profit
Despite China Isotope & Radiation Corporation's (HKG:1763) recent earnings report having lackluster headline numbers, the market responded positively. Sometimes, shareholders are willing to ignore so
Why Investors Shouldn't Be Surprised By Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (SZSE:002399) Low P/S
You may think that with a price-to-sales (or "P/S") ratio of 2.8x Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SZSE:002399) is a stock worth checking out, seeing as almost half of all the Pharmac
Cinda Biotech (01801.HK) grants 3,371 share options and 9551 restricted shares
Gelonghui, May 3, 丨 Cinda Biotech (01801.HK) announced that on May 3, 2024, the company granted 3,371 share purchase rights to independent non-executive director Chen Shuyun in accordance with the terms of the initial public offering after-sales employee share ownership plan, subject to Chen's acceptance. The board of directors announced that on May 3, 2024, the company granted 9551 restricted shares to Chen Shuyun in accordance with the 2020 Restricted Shares Plan, subject to Chen's acceptance and approval by independent shareholders at the Annual General Meeting of Shareholders.
Cinda Biotech (01801): Zhang Qian was appointed as Executive Director and Strategy Committee Member
Cinda Biotech (01801) announced that since May 3, 2024, Mr. Chen Shuyun has been appointed as an independent non-...
Xiansheng Pharmaceutical (02096) spent HK$781,600 to buy back 138,000 shares on May 3
According to the Zhitong Finance App, Xiansheng Pharmaceutical (02096) announced that on May 3, 2024, the company spent HK$781,600 to repurchase 138,000 shares at a repurchase price of HK$5.64-5.67 per share.
CSPC Group (01093.HK) cancelled 26.628 million shares on May 3
Gelonghui, May 3, 丨 Shiyao Group (01093.HK) announced that on May 3, 2024, 26.628 million shares have been cancelled.
CCB International: Maintaining Cinda Biotech's (01801) “Outperform the Market” rating and raising the target price to HK$54.7
According to CCB International, Cinda Biotech (01801) is one of the bank's preferred stocks in the Chinese pharmaceutical industry.
Changes in Hong Kong stocks | CRO concept stocks fell across the board, Yakming Kangde (02359) fell more than 7%, leading the decline, and the company's profit margin for the first quarter fell short of expectations
CRO concept stocks fell across the board. As of press release, Yao Ming Kangde (02359) fell 6.47% to 36.15 yuan; Gloria Ying (06821) fell 5.33% to 63.05 yuan; Kanglong Chemical (03759) fell 4.96% to HK$9.96.
Hong Kong Stock Concept Tracking | China's Nuclear Medicine Industry Attracts Attention (with concept stocks), the key technology for batch online irradiation production of isotopes
Various short-half-life medical isotopes that are currently in short supply in China will enter the large-scale production stage after the supporting plant is completed and put into operation in the second half of this year.
YiChang HEC ChangJiang Pharmaceutical's (HKG:1558) Earnings May Just Be The Starting Point
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) strong earnings report was rewarded with a positive stock price move. Our analysis found some more factors that we think are good for shar
Here's Why CK Life Sciences Int'l. (Holdings) (HKG:775) Has A Meaningful Debt Burden
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
We Think China Medical System Holdings Limited's (HKG:867) CEO Compensation Package Needs To Be Put Under A Microscope
Key Insights China Medical System Holdings to hold its Annual General Meeting on 9th of May CEO Kong Lam's total compensation includes salary of CN¥5.09m Total compensation is 80% above industry a
Antengene Logs Slimmer Loss in 2023 Despite Revenue Drop
Antengene's (HKG:6996) attributable loss narrowed to 581.2 million yuan, or 0.94 yuan per share, in 2023 from 601.5 million yuan, or 0.97 yuan per share, in 2022, according to the company's annual rep
PHARMARON To Go Ex-Dividend On June 27th, 2024 With 0.22051 HKD Dividend Per Share
May 2nd - $PHARMARON(03759.HK)$ is trading ex-dividend on June 27th, 2024. Shareholders of record on June 28th, 2024 will receive 0.22051 HKD dividend per share. The ex-dividend date is June 27th,
China Medical Network (00383.HK) Stock Short Name Change Effective May 7
Gelonghui, May 2, 丨 China Medical Network (00383.HK) announced that the English stock abbreviation of the company used to trade shares on the Stock Exchange will be changed from “CHINA MED&HCARE” to “TIANAN MEDICARE”, while the Chinese stock abbreviation will be changed from “China Medical Network” to “Tianandongjian”, effective from 9:00 a.m. on May 7, 2024.
Sihuan Pharmaceutical Unit's Lung Cancer Drug NDA Accepted by NMPA, Stocks Shoot Over 10%
Sihuan Pharmaceutical Holdings Group (HKG:0460) said its New Drug Application (NDA) to China's National Medical Products Administration (NMPA) was accepted for the lung cancer drug Dexitinib tablets,
Changes in Hong Kong stocks | Cinda Biotech (01801) is now up more than 9%, and total product revenue in the first quarter has increased by more than 60%. The company will release multiple clinical data at ASCO
Cinda Biotech (01801) is now up more than 9%. As of press release, it is up 9.02% to HK$41.7, with a turnover of HK$265 million.
Sihuan Pharmaceutical (00460.HK): Xuanzhu Biotech independently developed a Class 1 innovative drug “daxitinib tablets” and applied for marketing to the State Drug Administration and accepted
On May 2, Ge Longhui Pharmaceutical (00460.HK) announced that the Class 1 innovative anti-tumor drug “daxitinib tablets” (product code: XZP-3621) independently developed by Xuanzhu Biotechnology Co., Ltd. (“Xuanzhu Biology”), a non-wholly-owned subsidiary of the Group, has been declared for marketing and accepted by China's National Drug Administration (“State Drug Administration”). The specific indications for this report are: It is suitable for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) positive for anaplastic lymphoma kinase (ALK). Dacitinib tablets submitted a marketing application for Xuanzhu Biotech and
Simcere Pharmaceutical Group's (HKG:2096) Shareholders Have More To Worry About Than Only Soft Earnings
The subdued market reaction suggests that Simcere Pharmaceutical Group Limited's (HKG:2096) recent earnings didn't contain any surprises. Our analysis suggests that along with soft profit numbers, in
Golden Throat's Profit Declines 11% in 2023
Golden Throat Holdings Group (HKG:6896) recorded an 11% decline in attributable profit for 2023 to 250.2 million yuan from 281.2 million yuan in 2022, according to the company's annual report. Earning